Apollomics (APLM) vs Tonix Pharmaceuticals (TNXP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Apollomics (APLM) has outperformed Tonix Pharmaceuticals (TNXP) over the past year, gaining 7.4% versus a loss of 85.2%. Over five years, APLM leads with a -98.4% price change compared with -100.0% for TNXP. Tonix Pharmaceuticals is the larger company by market cap ($46.2 million vs $45.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APLM | TNXP |
|---|---|---|
| Share price | $15.54 | $2.38 |
| Market cap | $45.28M | $46.25M |
| 1-day change | -6.92% | -6.67% |
| YTD return | -16.90% | -84.76% |
| 1-year return | +7.43% | -85.22% |
| 5-year return | -98.43% | -100.00% |
| EPS (TTM) | $-0.25 | $-12.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $13.11M |
| Revenue growth (YoY) | — | +29.85% |
| Net income (latest FY) | $-53.86M | $-124.02M |
| Gross margin | — | 49.34% |
| Operating margin | — | -959.05% |
| Net margin | — | -946.22% |
| 52-week high | $28.29 | $20.56 |
| 52-week low | $12.58 | $2.30 |
| Distance from 52-week high | -45.09% | -88.42% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +1769.75% |
| Average volume | 11.07K | 838.83K |
| Shares outstanding | 2.91M | 19.43M |
| Employees | 14 | 142 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- APLM has outperformed TNXP by 92.7 percentage points over the past year.
About Apollomics
APLM stock →Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
About Tonix Pharmaceuticals
TNXP stock →Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia.
Health Care · Biotechnology: Pharmaceutical Preparations · 142 employees
APLM vs TNXP FAQ
Which is bigger, Apollomics or Tonix Pharmaceuticals?
Tonix Pharmaceuticals (TNXP) is larger, with a market capitalization of $46.25M compared with $45.28M for Apollomics (APLM).
Which stock has performed better over the past year, APLM or TNXP?
APLM returned +7.43% over the past 12 months, compared with -85.22% for TNXP (price return, excluding dividends). Past performance does not predict future results.
Are Apollomics and Tonix Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.